Please read the full Prescribing Information and
Instructions for Use.

CONFIDENCE IN THE CLASSROOM

Team up with VALTOCO^® (diazepam nasal spray)
to change the seizure rescue experience at school

Tue, May 9 • 12:00 PM - 1:00 PM ET

Presented by:
Beck Reyes, MSN, CPNP, CNRN

Wed, May 10 • 3:00 PM - 4:00 PM ET

Presented by:
Britton Zuccarelli, MD

Tue, May 16 • 1:00 PM - 2:00 PM ET

Presented by:
Beck Reyes, MSN, CPNP, CNRN

Thurs, May 18 • 8:00 PM - 9:00 PM ET

Presented by:
Britton Zuccarelli, MD

Presenters

Ms Reyes earned her Master of Science in Nursing with a dual certification as a nurse practitioner and clinical nurse specialist from the University of California in Los Angeles. She has practiced as a nurse practitioner in general pediatrics and multiple sub-specialties including multiple sclerosis, inflammatory bowel disease, cystic fibrosis, and cleft palate, and now pediatric neurology. Ms Reyes is certified by the Pediatric Nursing Certification Board as a Certified Pediatric Nurse Practitioner and by the American Board of Neuroscience Nursing as a Certified Neuroscience Registered Nurse.

Ms Reyes is currently a faculty lecturer at the UCLA School of Nursing and a nurse practitioner in the Division of Pediatric Neurology at UCLA Mattel Children’s Hospital. She is a member of the Association of Child Neurology Nurses, National Association of Pediatric Nurse Practitioners, and Sigma Theta Tau International. Ms Reyes has contributed nearly a dozen abstracts and presentations to national scientific meetings and has recently published an article in the Journal of Pediatric Health Care.

Dr Zuccarelli completed her undergraduate degree at Cornell College, Mount Vernon, Iowa, and earned her medical degree from University of Kansas School of Medicine, Kansas City, Kansas. She completed her residency at Children’s Mercy Hospital, Kansas City, Missouri, in child neurology.

She is a child neurologist at Salina Pediatric Care and specializes in child neurology sub-specialty pediatric care. At the Salina Regional Health Center (SRHC), she serves as Medical Director for both the Concussion Program and the Infant Child Development Program. Additionally, Dr Zuccarelli is a Clinical Assistant Professor, Department of Neurology, at the University of Kansas School of Medicine, Salina campus. Dr Zuccarelli is President of the Saline County Medical Society and a member of the Child Neurology Society and the American Academy of Neurology. In addition, she participates in the SRHC Strategic Planning Committee, SRHC Stroke Peer Review Committee, and SRHC Pediatric Subsection Committee. Dr Zuccarelli is an American Heart Association Pediatric Advanced Life Support Instructor. She has presented dozens of times on neurology.

Confidence in the Classroom

Team up with VALTOCO^® (diazepam nasal spray) to change the seizure rescue experience at school

Indication

VALTOCO^® (diazepam nasal spray) is indicated for the acute treatment of intermittent, stereotypic episodes of frequent seizure activity (ie, seizure clusters, acute repetitive seizures) that are distinct from a patient’s usual seizure pattern in patients with epilepsy 6 years of age and older.

IMPORTANT SAFETY INFORMATION

WARNING: RISKS FROM CONCOMITANT USE WITH OPIOIDS; ABUSE, MISUSE, AND ADDICTION; and DEPENDENCE AND WITHDRAWAL REACTIONS

Concomitant use of benzodiazepines and opioids may result in profound sedation, respiratory depression, coma, and death. Reserve concomitant prescribing of these drugs for patients for whom alternative treatment options are inadequate. Limit dosages and durations to the minimum required. Follow patients for signs and symptoms of respiratory depression and sedation.
The use of benzodiazepines, including VALTOCO, exposes users to risks of abuse, misuse, and addiction, which can lead to overdose or death. Abuse and misuse of benzodiazepines commonly involve concomitant use of other medications, alcohol, and/or illicit substances, which is associated with an increased frequency of serious adverse outcomes. Before prescribing VALTOCO and throughout treatment, assess each patient’s risk for abuse, misuse, and addiction.
The continued use of benzodiazepines may lead to clinically significant physical dependence. The risks of dependence and withdrawal increase with longer treatment duration and higher daily dose. Although VALTOCO is indicated only for intermittent use, if used more frequently than recommended, abrupt discontinuation or rapid dosage reduction of VALTOCO may precipitate acute withdrawal reactions, which can be life-threatening. For patients using VALTOCO more frequently than recommended, to reduce the risk of withdrawal reactions, use a gradual taper to discontinue VALTOCO.

Contraindications: VALTOCO is contraindicated in patients with:

Hypersensitivity to diazepam
Acute narrow-angle glaucoma

Central Nervous System (CNS) Depression

Benzodiazepines, including VALTOCO, may produce CNS depression. Caution patients against engaging in hazardous activities requiring mental alertness, such as operating machinery, driving a motor vehicle, or riding a bicycle, until the effects of the drug, such as drowsiness, have subsided, and as their medical condition permits.

The potential for a synergistic CNS-depressant effect when VALTOCO is used with alcohol or other CNS depressants must be considered, and appropriate recommendations made to the patient and/or care partner.

Suicidal Behavior and Ideation

Antiepileptic drugs (AEDs), including VALTOCO, increase the risk of suicidal ideation and behavior. Patients treated with any AED for any indication should be monitored for the emergence or worsening of depression, suicidal thoughts or behavior, and/or unusual changes in mood or behavior.

Glaucoma

Benzodiazepines, including VALTOCO, can increase intraocular pressure in patients with glaucoma. VALTOCO may be used in patients with open-angle glaucoma only if they are receiving appropriate therapy. VALTOCO is contraindicated in patients with narrow-angle glaucoma.

Neonatal Sedation and Withdrawal Syndrome

Use of VALTOCO late in pregnancy can result in sedation (respiratory depression, lethargy, hypotonia) and/or withdrawal symptoms (hyperreflexia, irritability, restlessness, tremors, inconsolable crying, and feeding difficulties) in the neonate. Monitor neonates exposed to VALTOCO during pregnancy or labor for signs of sedation and monitor neonates exposed to VALTOCO during pregnancy for signs of withdrawal; manage these neonates accordingly.

Risk of Serious Adverse Reactions in Infants due to Benzyl Alcohol Preservative

VALTOCO is not approved for use in neonates or infants. Serious and fatal adverse reactions, including “gasping syndrome,” can occur in neonates and low-birth-weight infants treated with benzyl alcohol–preserved drugs, including VALTOCO. The “gasping syndrome” is characterized by central nervous system depression, metabolic acidosis, and gasping respirations. The minimum amount of benzyl alcohol at which serious adverse reactions may occur is not known.

Adverse Reactions

The most common adverse reactions (at least 4%) were somnolence, headache, and nasal discomfort.

Diazepam, the active ingredient in VALTOCO, is a Schedule IV controlled substance.

To report SUSPECTED ADVERSE REACTIONS, contact Neurelis, Inc. at 1-866-696-3873 or FDA at 1-800-FDA-1088 (www.fda.gov/medwatch).

Please read full Prescribing Information, including Boxed Warning, for additional important safety information.